From: Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study
Patient characteristics | Total (%) n = 464 | Deceased (% of the total) | Median (IQR) survival (months) | p value |
---|---|---|---|---|
Gender | 0.56 | |||
Male | 353 (76) | 292 (83) | 14.2 (7.0-29.5) | |
Female | 111 (24) | 100 (90) | 14.2 (9.3-28.9) | |
Age (by quartile) | 0.84 | |||
< 54 years | 112 (24) | 96 (86) | 13.7 (7.7-28.8) | |
54-60 years | 112 (24) | 95 (85) | 13.5 (8.4-30.1) | |
60-67 years | 117 (25) | 96 (82) | 15.6 (7.3-30.1) | |
≥ 67 years | 123 (27) | 105 (85) | 13.8 (6.9-27.9) | |
Performance status | 4.10−4 | |||
0 | 183 (39) | 149 (81) | 16.8 (10.3-35.5) | |
1 | 261 (56) | 224 (86) | 12.2 (6.4-28.0) | |
2 | 20 (4) | 19 (95) | 6.0 (2.8-13.9) | |
Charlson comorbidity index[[18]] | 0.71 | |||
0 | 378 (81) | 321 (85) | 13.6 (7.3-28.9) | |
≥ 1 | 86 (19) | 71 (83) | 15.3 (7.3-29.5) | |
Histology | <10−4 | |||
Adenocarcinoma | 279 (60) | 247 (89) | 13.7 (7.1-27.9) | |
Squamous cell carcinoma | 112 (24) | 79 (71) | 20.2 (9.2-63.5) | |
Large cell carcinoma | 73 (16) | 66 (90) | 10.5 (6.3-20.2) | |
Cancer spread | <10−4 | |||
Localised (II IIIA) | 83 (18) | 49 (59) | 35.5 (18.5-not reached) | |
Advanced (IIIB) | 97 (21) | 75 (87) | 20.2 (10.8-41.5) | |
Metastatic (IV) | 284 (61) | 268 (94) | 10.5 (5.9-18.6) | |
Platinum-based doublet | 0.26 | |||
Platinum-gemcitabine | 179 (39) | 150 (84) | 15.8 (8.0-33.2) | |
Platinum-vinorelbine | 77 (17) | 64 (82) | 15.2 (8.3-28.9) | |
Platinum-docetaxel | 74 (16) | 64 (86) | 12.7 (7.3-21.8) | |
Platinum-paclitaxel | 70 (15) | 61 (87) | 11.3 (4.3-26.9) | |
Platinum-pemetrexed | 64 (14) | 54 (84) | 16.0 (8.1-29.9) | |
Tumour response | <10−4 | |||
Complete/partial response | 146 (31) | 108 (74) | 20.8 (10.8-43.9) | |
Stable disease | 245 (53) | 213 (87) | 14.6 (8.2-28.8) | |
Progressive disease | 73 (16) | 71 (97) | 4.5 (2.7-8.3) |